Welcome to our dedicated page for GALECTIN THERAPEUTICS SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics Inc. filed an 8-K stating it furnished a press release with results of operations and financial condition for the nine months ended September 30, 2025, along with a business update. The information under Item 2.02 is furnished, not filed, and the press release is attached as Exhibit 99.1 dated November 14, 2025.
Galectin Therapeutics (GALT) filed its Q3 2025 10‑Q, reporting a net loss of $8.184M for the quarter and $25.336M for the nine months. Operating expenses for the nine months fell to $16.720M from $30.005M a year ago as R&D tapered with trial activity.
Cash and equivalents were $11.525M at Sept 30, 2025. Net cash used in operations was $17.833M, partly offset by $14.238M from financing, including related‑party credit draws and $2.071M via the at‑the‑market program. The company states substantial doubt about its ability to continue as a going concern, though it believes existing cash and a new $10M line of credit signed on July 8, 2025 can fund planned operations through June 30, 2026.
Total assets were $12.865M against liabilities of $136.445M, resulting in a stockholders’ deficit of $125.303M. The NAVIGATE trial’s top‑line showed a 49.3% variceal incidence reduction in the per‑protocol population at 2 mg/kg (p<0.05); U.S. completers saw a 68.1% reduction (p=0.02). Safety remained comparable to placebo with no drug‑related SAEs reported.
Galectin Therapeutics (GALT) CEO and Director reported a Rule 10b5-1 trade. On 11/10/2025, he exercised 1,867 stock options at $2.39 and sold 1,867 common shares at a weighted average price of $6.0269 (sales ranged from $6.00 to $6.12). The exercised options were granted on 12/14/2018 and vested 100%.
Following the transactions, he beneficially owns 832,592 shares directly, plus 2,000 shares indirectly as custodian for a minor child. He also reports 22,363 derivative securities (options) beneficially owned.
Galectin Therapeutics (GALT) CFO Jack W. Callicutt reported option exercises and same‑day sales on 11/10/2025 under a Rule 10b5‑1 plan adopted on April 17, 2025. He exercised stock options for 5,291 shares (strike prices: $1.11, $1.23, and $1.98) and sold the same number of shares in open‑market transactions.
Sales were executed at weighted average prices of $6.022, $6.0266, and $6.0298, with individual trades ranging from $6.00 to $6.14. Following these transactions, he directly owned 7,614 shares of common stock.
Galectin Therapeutics (GALT) reported that it presented results from its NAVIGATE trial at the AASLD 2025 Annual Meeting and posted an updated Corporate Presentation. The company also issued a press release; both materials were provided as Exhibits 99.1 and 99.2.
The materials were furnished under Item 7.01 of a Form 8-K and are not deemed filed under the Exchange Act. The disclosures include forward-looking statements subject to the cautionary notes in the exhibits and other SEC reports.
Galectin Therapeutics (GALT) reported an insider transaction by its President and CEO, who is also a Director. On 11/05/2025, the executive exercised 200 stock options at $2.39 and sold 200 common shares at $6.00, executed under a Rule 10b5-1 plan.
Following these transactions, the executive reported 832,592 common shares held directly. An additional 2,000 shares are held indirectly as custodian for a minor child under the Uniform Transfers to Minors Act, with beneficial ownership disclaimed. The exercised options were from a grant that vested 100% on 12/14/2018 and expire on 12/14/2027, with 24,230 derivative securities reported as beneficially owned after the transaction.
Galectin Therapeutics (GALT) Form 4: CFO Jack W. Callicutt exercised stock options for 600 shares and sold 600 shares on 11/05/2025 under a Rule 10b5-1 plan. Exercises occurred at $1.98, $1.11, and $1.72 per share, with sales at $6. Following these transactions, he held 7,614 shares directly.
Galectin Therapeutics (GALT) reported insider transactions by its President and CEO, who is also a Director. On 11/03/2025 and 11/04/2025, the officer exercised stock options at $2.39 per share for 1,300 and 14,420 shares, respectively, and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on April 17, 2025. Sales were executed at weighted average prices of $6.01 (range: $6.00–$6.01) and $6.07 (range: $6.00–$6.20). Following these transactions, the officer directly beneficially owned 832,592 common shares and held 2,000 shares indirectly as custodian for a minor child under the UTMA. The reported options vested on December 14, 2018 and expire on December 14, 2027.
Galectin Therapeutics (GALT) reported insider transactions by CFO Jack W. Callicutt. On November 3–4, 2025, he exercised employee stock options at $1.11, $1.72, and $1.98 per share and sold the resulting shares under a pre‑arranged Rule 10b5‑1 plan.
Sales on November 3 were executed at a weighted average price of $6.01 (transactions ranged from $6.00–$6.01). On November 4, sales were executed at a weighted average price of $6.07 (range $6.00–$6.25). Individual lots included 1,300, 1,260, and 1,250 shares on November 3, and 8,914, 8,974, and 10,741 shares on November 4.
Following these transactions, the CFO beneficially owned 7,614 shares directly. The options referenced were from grants with previously disclosed vesting schedules.
Galectin Therapeutics (GALT) reported insider transactions by 10X Fund, L.P., 10X Capital Management, LLC, and Director James C. Czirr on 10/22/2025. The filing lists two open‑market sales: 20,000 shares at $4.93 and 30,000 shares at $4.94.
Following these sales, the reporting persons show 5,872,207 shares beneficially owned. The form indicates direct ownership for the reported balance and includes standard footnotes stating that certain parties may be deemed to have indirect beneficial ownership, with ownership disclaimed except to the extent of pecuniary interest.